Person:
Candel González, Francisco Javier

Profile Picture
First Name
Francisco Javier
Last Name
Candel González
URI
https://hdl.handle.net/20.500.14352/79145
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Medicina
Department
Medicina
Area
Microbiología
Identifiers
UCM identifierScopus Author IDDialnet ID

Filters

2004 - 200912020 - 20243
Reset filters

Settings

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Biomarkers of stable and decompensated phases of heart failure with preserved ejection fraction
    (International journal of cardiology, 2022) Anguita Mandly, Eduardo Luis; Chaparro, Alberto; Candel González, Francisco Javier; Ramos Acosta, Carlos; Torrejón, María José; Llopis García, Guillermo; Suárez Cadenas, María del Mar; Matesanz, Mayra; González Del Castillo, Juan María; Martín Sánchez, Francisco Javier; Anguita, Eduardo
    Background Heart failure with preserved ejection fraction (HFpEF) is a disorder related to patient comorbidities and aging. Whether mitochondrial dysfunction is present during HFpEF decompensation versus the stable phase is largely unknown. The aim of the present study was to identify mitochondrial and cell metabolism blood biomarkers in older patients with acute and stable HFpEF. Methods Peripheral blood biomarkers were investigated in a group of eight to 12 patients aged 80–96 years and diagnosed with HFpEF first when they were in decompensated phase and then at least three months later in stable phase. Their data were compared to two control groups with an equal number of participants and sex proportions. One group was age matched and the other included individuals aged between 22 and 44 years. Results Decompensated patients experienced an increased mitochondrial superoxide production and mitochondrial mass, lower mitochondrial DNA copy number and LDHB expression, and higher lactate level compared to the stable stage. The stable phase was characterized by a sharp reduction in formate level. Multivariate analysis indicated that formate, lactate, and histidine can distinguish both of the HFpEF phases. Many of these parameters, including LDHB, lactate, formate, and mitochondrial mass, followed an age-related pattern, with acute HFpEF at its apex or nadir, suggesting that it represents an exacerbation of an aging-related process. Conclusions We identified distinct blood biomarkers of chronic and decompensated HFpEF phases. The data underlined the relationship between HFpEF and aging. These findings could be used to monitor patients and might be therapeutically targeted.
  • Thumbnail Image
    Item
    Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production
    (International journal of molecular sciences, 2024) Ramos Acosta, Carlos; Huerta Pantoja, Laura; Salazar Hidalgo, Milton Eduardo; Mayol, Elsa; Jiménez Vega, Selene; García Peña, Pablo; Jordi Cruz, Jenifeer; Baquero, Cristina; Porras Gallo, María Almudena; Íñigo Rodríguez, Belén; Benavente Cuesta, Celina; Candel González, Francisco Javier; Anguita Mandly, Eduardo Luis
    Multiple myeloma is an incurable plasma cell malignancy. Most patients end up relapsing and developing resistance to antineoplastic drugs, like bortezomib. Antibiotic tigecycline has activity against myeloma. This study analyzed tigecycline and bortezomib combination on cell lines and plasma cells from myeloma patients. Apoptosis, autophagic vesicles, mitochondrial mass, mitochondrial superoxide, cell cycle, and hydrogen peroxide were studied by flow cytometry. In addition, mitochondrial antioxidants and electron transport chain complexes were quantified by reverse transcription real-time PCR (RT-qPCR) or western blot. Cell metabolism and mitochondrial activity were characterized by Seahorse and RT-qPCR. We found that the addition of tigecycline to bortezomib reduces apoptosis in proportion to tigecycline concentration. Supporting this, the combination of both drugs counteracts bortezomib in vitro individual effects on the cell cycle, reduces autophagy and mitophagy markers, and reverts bortezomib-induced increase in mitochondrial superoxide. Changes in mitochondrial homeostasis and MYC upregulation may account for some of these findings. These data not only advise to avoid considering tigecycline and bortezomib combination for treating myeloma, but caution on the potential adverse impact of treating infections with this antibiotic in myeloma patients under bortezomib treatment.
  • Thumbnail Image
    Item
    Virological Correlates of IgM–IgG Patterns of Response to SARS-CoV-2 Infection According to Targeted Antigens
    (Viruses, 2021) Barreiro, Pablo; Candel González, Francisco Javier; Sanz, Juan Carlos; San Román Montero, Jesús; del Mar Carretero, María; Pérez Abeledo, Marta; Ramos, Belén; Viñuela Prieto, José Manuel; Canora, Jesús; Martínez Peromingo, Francisco Javier; Zapatero, Antonio
    The virological meaning of the different patterns of serology in COVID-19 has been little examined in clinical settings. Asymptomatic subjects with IgM-spike (S) and IgG-nucleocapsid (N) determinations by chemiluminescence were studied for SARS-CoV-2 shedding in respiratory secretions by transcription-mediated amplification (TMA). In subjects showing IgM-S positive and IgG-N negative, IgG-S was determined by lateral flow assay. A total of 712 individuals were tested: 30.0% presented IgM-S(+)/IgG-N(−), 25.8% had IgM-S(+)/IgG-N(+) and 44.2% had IgM-S(−)/IgG-N(+); the proportion with TMA(+) were comparable in these three groups: 12.1, 8.7 and 10.5%, respectively. In individuals with IgM-S(+)/IgG-N(−), IgG-S(+) was detected in 66.5%. The frequency of IgM-S(+)/IgG-S(−) in the total population was 10.0%, of whom 24.1% had TMA(+); the chances for TMA(+) in subjects with an IgM-S(+) alone pattern were 2.4%. Targeting of the same SARS-CoV-2 antigen seems to be better for the characterization of IgM/IgG patterns of response. IgM-S(+) alone reactivity is rare, and a small proportion is associated with viral shedding.
  • Thumbnail Image
    Item
    Profilaxis tromboembólica en la fibrilación auricular : análisis de cinco años de seguimiento ambulatorio en un área centro de Madrid
    (2004) Candel González, Francisco Javier; Candel Monserrate, Indalecio
    La fibrilación auricular continua siendo un problema médico de primera magnitud, debido en gran medida a sus consecuencias fisiopatológicas. Entre ellas queremos destacar el elevado riesgo embólico que conlleva. Son numerosos los estudios que demuestran la mayor eficacia de la anticoagulación con respecto a la antiagregación o la ausencia de profilaxis, sin embargo, el empleo de los anticoagulantes está infrautilizado en nuestros medio. El presente estudio es un análisis retrospectivo del tipo de profilaxis tromboembólica utilizada en una cohorte de pacientes en un área centrica de Madrid (area de Chamberi) y sus consecuencias embólicas a lo largo de cinco años, tambien se analizó el indice de sangrados y la mortalidad. Las conclusiones del presente estudio reflejaron una mayor efectividad de la terapia anticoagulante en términos de disminución del evento embólico y una disminución de la mortalidad. No se objetivaron diferencias estadisticamente significativas en terminos de sangrado en el grupo anticoagulado con respecto al grupo antiagregado o al grupo sin profilaxis. La antiagreagación demostró ser más efectiva que la ausencia de tratamiento en terminos de disminución del evento embólico y mortalidad. Ademas se constató una infrautilización de la anticoagulación oral al inicio del seguimiento que se cifraba en torno al 12% en la fibrilación auricular no valvular y al 37% en la fibrilación auricular valvular. Estas cifras se incrementaron al concluir el seguimiento a un 25% en las no valvulares y un 61% en valvulares